Non-alcoholic fatty liver organ model and preparation method and application thereof

By using non-toxic free fatty acid treatment methods and specific medium components in liver organoids, a stable and low-dose non-alcoholic liposus liver organoid model was constructed, and the instability problem caused by the use of DMSO in the prior art was solved. , effective simulation of liver steatosis.

CN118909928AInactive Publication Date: 2024-11-08JIANGZHONG PHARMA CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411408547.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-10
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The use of the toxic solvent DMSO in the preparation process of the existing non-alcoholic fatty liver organoid model results in unstable model construction effect and high amount of free fatty acid reserve solution, making it difficult to effectively simulate the physiological and pathological status of the liver.

Method used

Using a non-toxic and stable free fatty acid treatment method, a non-alcoholic fatty liver organoid model is constructed by contacting the liver organoid with a solution containing oleic acid and palmitic acid, combining bovine serum albumin and specific culture medium components, and avoiding the use of DMSO and specific ingredients are added to Advanced DMEM/F12 medium to induce steatosis.

Benefits of technology

A non-alcoholic fatty liver organoid model with non-toxicity, high stability and low raw material usage is realized, which can effectively simulate the steatosis process of the liver, and the free fatty acid solution does not precipitate in the culture medium, ensuring the stability and low model Dosage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909928A_ABST
    Figure CN118909928A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicines, in particular to a non-alcoholic fatty liver organ model as well as a preparation method and application thereof. The preparation method comprises a step of contacting a liver organ with a solution containing free fatty acid in a culture medium; the concentration of the free fatty acid in the culture medium is at least 500 [mu] M; the preparation method of the solution containing the free fatty acid comprises the following steps: (1) taking oleic acid and palmitic acid, and preparing into a solution A by using 100% ethanol; and (2) mixing a buffer solution containing bovine serum albumin with the solution A until the solution is clear and transparent for later use. The invention has the advantages of no toxicity, high stability and low raw material consumption.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a non-alcoholic fatty liver organoid model and a preparation method and application thereof. Background Art

[0002] Non-alcoholic fatty liver disease (NAFLD) refers to a clinical pathological syndrome characterized by excessive fat deposition in hepatocytes, excluding alcohol and other clear liver-damaging factors. It is an acquired metabolic stress liver injury closely related to insulin resistance and genetic susceptibility. It includes simple fatty liver (SFL), non-alcoholic steatohepatitis (NASH) and its related cirrhosis. NAFLD is a potentially serious disease, mainly caused by abnormal accumulation of fat in the liver, leading to fatty degeneration of the liver. This condition is often accompanied by metabolic abnormalities, including obesity, diabetes and hyperlipidemia, which may work together to lead to further progression of the disease, which can develop into non-alcoholic steatohepatitis (NASH). If not treated in time, it may even develop into liver fibrosis, cirrhosis and liver cancer.

[0003] The drug treatment process of NAFLD also requires intervention through lifestyle changes, including low-calorie diet, weight loss and exercise. Current research focuses mostly on the late and clinical NASH stages, while there are fewer studies on early diseases and their pathogenesis. Therefore, effective research on the first stage of non-alcoholic fatty liver disease, the fatty degeneration stage, is crucial in minimizing liver damage and disease progression.

[0004] Organoids are three-dimensional (3D) cell cultures that have the key structural and functional characteristics of specific organs. Compared with human cell lines and animal models, organoids reproduce the three-dimensional structure of primary tissues, are closer to the structural and functional characteristics of in vivo tissues, can simulate the structural and functional characteristics of in vivo organs, and are widely used in disease modeling, drug screening and drug safety evaluation.

[0005] Primary hepatocytes have now become one of the main sources of liver organoids. More and more studies have shown that mature hepatocytes still have stemness potential and proliferation capacity in a specific environment. The high genetic stability of tissue-derived liver organoids and their high similarity to organs make them a new choice for in vitro drug testing. Therefore, although it is difficult to maintain proliferation capacity and metabolic function during long-term in vitro expansion, tissue-derived organoids still have high research value and broad clinical application prospects.

[0006] Chinese patent publication number CN116426461A discloses an in vitro fatty liver organoid model and its preparation method, which specifically includes dissolving palmitic acid (1M) and oleic acid (2M) in DMSO to prepare a free fatty acid (FFAs) stock solution, and storing it at -20°C; then, adding bovine serum albumin (final concentration of 1% w / v), free fatty acid stock solution (final concentration of 900μM) and glucose (final concentration of 55mM) to DMEM complete medium, heating the medium in a water bath at 37°C for 2 hours to allow the free fatty acids to bind to the albumin; finally, adjusting the DMSO concentration in the medium so that the final DMSO concentration of the fatty liver organoid induction medium containing different concentrations of free fatty acids is 0.045%. However, the toxic solvent DMSO needs to be used in the preparation process of the model, and the method of preparing free fatty acids is easy to precipitate after adding them to the culture medium, resulting in unstable effect of model construction, and the amount of free fatty acid stock solution is high.

[0007] Therefore, it is very necessary to develop a non-alcoholic fatty liver organoid model and its preparation method and application that can solve the above-mentioned technical problems. Summary of the invention

[0008] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a non-alcoholic fatty liver organoid model that is non-toxic, highly stable, and uses low amounts of raw materials, as well as a preparation method and application thereof.

[0009] The present invention is based on liver organoids, especially mouse liver organoids, and focuses on the first stage of non-alcoholic fatty liver disease (NAFLD) - the fatty degeneration stage. Through free fatty acid treatment, a non-alcoholic fatty liver organoid model is constructed, aiming to better simulate the physiological behavior and pathological state of the liver.

[0010] The present invention is achieved through the following technical solutions: A method for preparing a non-alcoholic fatty liver organoid model, comprising the step of contacting a liver organoid with a solution containing free fatty acids (FFA) in a culture medium; the concentration of the free fatty acids in the culture medium is at least 500 μM, preferably 500 μM; The preparation method of the solution containing free fatty acids comprises the following steps: (1) Take oleic acid and palmitic acid and prepare solution A with 100% ethanol; (2) Mix the buffer solution containing bovine serum albumin with solution A until the solution becomes clear and transparent. Set aside.

[0011] In some embodiments of the present invention, the free fatty acids consist of oleic acid and palmitic acid in a molar ratio of 1:1.

[0012] In some embodiments of the present invention, the concentration of the free fatty acid in the culture medium is 500 μM.

[0013] In some embodiments of the present invention, the culture medium is prepared by adding 10±1 mM 4-hydroxyethylpiperazineethanesulfonic acid, 1% glutamine (volume percentage), 1% penicillin-streptomycin (volume percentage), 1:50B27 (the volume ratio of B27 to culture medium is 1:50, that is, the volume percentage is 2%), 1.25±0.1 mM N-acetylcysteine, 250±25ng / mL R-spondin-1, 50±5ng / mL EGF, 100±10ng / mL FGF10, 50±5ng / mL HGF, 10±1 nM gastrin, 10±1 mM nicotinamide, 3±0.3 μM CHIR99021, 1±0.1 μM A83-01 and 10±1 mM ROCK inhibitor Y-27632 to Advanced DMEM / F12 culture medium.

[0014] In some preferred embodiments of the present invention, the culture medium is prepared by adding 10 mM 4-hydroxyethylpiperazineethanesulfonic acid, 1% glutamine (volume percentage), 1% penicillin-streptomycin (volume percentage), 1:50 B27 (the volume ratio of B27 to culture medium is 1:50, that is, the volume percentage is 2%), 1.25 mM N-acetylcysteine, 250 ng / mL R-spondin-1, 50 ng / mL EGF, 100 ng / mL FGF10, 50 ng / mL HGF, 10 nM gastrin, 10 mM nicotinamide, 3 μM CHIR99021, 1 μM A83-01 and 10 mM ROCK inhibitor Y-27632 to Advanced DMEM / F12 culture medium.

[0015] In some embodiments of the present invention, the contacting time is 5-7 days.

[0016] In some embodiments of the present invention, prior to the contacting step, the liver organoids are dispersed in Matrigel to facilitate penetration of free fatty acids.

[0017] In some preferred embodiments of the present invention, the matrix gel is Matrigel (Corning, Catalog No. 354248), which is a soluble basement membrane extract isolated from Engelbreth-Holm-Swarm (EHS) mouse sarcoma, which is rich in ECM proteins such as laminin (main component), type IV collagen, heparan sulfate proteoglycans, entactin and various growth factors. In some embodiments of the present invention, in step (1), 100% ethanol is first used to prepare oleic acid mother liquor and palmitic acid mother liquor, and then mixed to obtain solution A, wherein the concentration of the oleic acid mother liquor is 200±20 mM, and the concentration of the palmitic acid mother liquor is 200±20 mM.

[0018] In step (2) of the present invention, a buffer solution containing bovine serum albumin is mixed with solution A, mainly to couple the bovine serum albumin with free fatty acids FFA (oleic acid, palmitic acid).

[0019] In some embodiments of the present invention, in step (2), the buffer solution containing bovine serum albumin is mixed with solution A and then placed in a 55±5° C. water bath for 15±5 min.

[0020] In some embodiments of the present invention, the buffer solution containing bovine serum albumin in step (2) is a PBS solution containing 10±1% bovine serum albumin. The buffer solution containing bovine serum albumin in the present invention does not contain free fatty acids.

[0021] In some embodiments of the present invention, the storage conditions for step (2) are: concentration of 8 mM, stored at -20°C.

[0022] The present invention also relates to a non-alcoholic fatty liver organoid model prepared by the above-mentioned preparation method.

[0023] The present invention also relates to the application of the above-mentioned non-alcoholic fatty liver organoid model in drug screening.

[0024] The drugs include, but are not limited to, drugs for treating simple fatty liver (SFL), and / or non-alcoholic steatohepatitis (NASH) and / or liver cirrhosis.

[0025] The beneficial effects of the present invention are: (1) The solution obtained by the method for preparing free fatty acids of the present invention is clear and transparent, and no precipitation occurs after being added to the culture medium, indicating that the solution has high stability and is conducive to the cultivation of a non-alcoholic fatty liver organoid model with stable performance.

[0026] (2) The present invention can induce fatty degeneration of liver organoids by adding only 500 μM free fatty acids to the culture medium, and the added amount is relatively low.

[0027] (3) The present invention avoids the use of toxic solvents such as DMSO and is more environmentally friendly. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Images of liver organoids collected using an inverted microscope on different days of culture. Scale bar = 100 μm.

[0029] Figure 2Immunofluorescence detection of the expression of hepatocyte markers (ALB, HNF4α) and hepatobiliary markers (CK19, Sox9) in mouse liver organoids. Scale bar = 100 μm. ALB is the abbreviation of Albumin, and CK19 is the abbreviation of Cytokeratin 19.

[0030] Figure 3 The dissolution conditions of the free fatty acid storage solutions prepared in Example 3. From left to right, they are ① PBS; ② DMSO; ③ anhydrous ethanol; ④ the free fatty acid storage solution prepared by the method for preparing a free fatty acid solution of the present invention.

[0031] Figure 4 The precipitation of each free fatty acid storage solution prepared in Example 3 in the liver organoid culture medium. From left to right, they are ① PBS; ② DMSO; ③ anhydrous ethanol; ④ the free fatty acid storage solution prepared by the method for preparing a free fatty acid solution of the present invention.

[0032] Figure 5 This is the result of detecting lipid droplet formation by Nile red staining in Example 5, scale bar = 50 μm.

[0033] Figure 6 These are the test results of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG) and lactate dehydrogenase (LDH) of the non-alcoholic fatty liver organoids in Example 6. DETAILED DESCRIPTION

[0034] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0035] The composition of the hepatic organoid culture medium used in each embodiment of the present invention is as follows: Advanced DMEM / F12 supplemented with 10 mM 4-hydroxyethylpiperazineethanesulfonic acid (HEPES), 1% glutamine, 1% penicillin-streptomycin, 1:50 B27 (without vitamin A), 1.25 mM N-acetylcysteine, 250 ng / mL R-spondin-1, 50 ng / mL EGF, 100 ng / mL FGF10, 50 ng / mL HGF, 10 nM gastrin, 10 mM nicotinamide, 3 μM CHIR99021, 1 μM A83-01 and 10 mM ROCK inhibitor Y-27632.

[0036] Example 1 Construction of mouse liver organoids 1.1 Isolation of primary mouse hepatocytes C57BL / 6 mice were killed, and the liver was removed and separated by collagenase digestion. 3 Place the liver tissue in a 60 mm culture dish and preheat the digestion solution (dissolve collagenase in sterile PBS to a concentration of 1 mg / ml) to 37°C; cut the tissue into pieces of approximately 0.5 mm 3 Transfer the chopped tissue to a 15 mL centrifuge tube, add 10 mL of pre-cooled PBS, repeat the washing step once (remove red blood cells and fat, including floating fat pieces); add 10 mL of digestion solution preheated to 37°C, and incubate at 37°C for 1 h.

[0037] 1.2 Liver organoid culture The isolated hepatocytes were filtered through a 70 μm filter, washed twice with cold AdDMEM / F12, resuspended in Matrigel (Corning, Cat. No. 354248) and inoculated to the bottom of a 24-well plate. The cells were incubated at 37°C for 15 minutes. After the Matrigel solidified, liver organoid culture medium was added. 14 days after seeding, the organoids were mechanically broken and re-seeded into new Matrigel. During the culture process, the culture medium was renewed every three days, and the organoids were usually passaged every 7-10 days, with a passage ratio of 1:3. Culture images of liver organoids captured using an inverted microscope on different days are shown below. Figure 1 As shown in Figure 2, primary hepatocytes gradually increase in size within 3 days of culture, form organoids after 6 days of culture, and can be expanded in long-term culture.

[0038] Example 2 Identification of liver organoids To verify whether the constructed liver organoid model reflects the molecular marker characteristics of primary hepatocytes, immunofluorescence was used to detect the expression of hepatocyte markers (ALB, HNF4α) and hepatobiliary markers (CK19, Sox9) in liver organoids. The specific operation is as follows: the organoids were washed twice with PBS, 1 mL of cold cell recovery solution was added, incubated at 4°C for 30 min, and the volume was supplemented to 10 mL with cold PBS (the more fully the matrix gel is diluted, the easier it is to remove, and incomplete removal of the matrix gel will result in a higher fluorescence background), centrifuged at 4°C, 70g for 3 min, and the supernatant was removed; the precipitated organoids were fixed with 4% paraformaldehyde at room temperature for 30 min, washed twice with PBS, incubated with 1% Triton X-100 for 20 min, blocked with 5% BSA for 40 min, and then incubated with the corresponding primary antibodies diluted with 5% BSA (CK19, Sox9, ALB, HNF4α; containing E-cadherin, i.e., E-cadherin, for cell membrane staining) at 4°C overnight; after washing three times with 0.5% BSA-PBS, the organoids were incubated with the corresponding secondary antibodies diluted with 5% BSA at room temperature for 1 h, washed three times with PBS, and anti-fluorescence quenchers (containing DAPI, 4'6-diamidino-2 -phenylindole, to stain the cell nucleus), and observed using a confocal fluorescence microscope. Figure 2 The secondary antibodies used were goat anti-rabbit IgG H&L (Alexa Fluor® 647) excitation / emission: 652 / 668 nm; goat anti-mouse IgG H&L (Alexa Fluor® 488) excitation / emission: 495 / 519 nm. Figure 2 It can be seen that the liver organoid model constructed above successfully expressed hepatocyte markers (ALB, HNF4α) and bile duct markers (CK19, Sox9) in liver organoids, reflecting the molecular marker characteristics of primary hepatocytes.

[0039] Example 3 Preparation of free fatty acid solution Take oleic acid and palmitic acid in equal molar proportions and mix them, respectively, using ① PBS; ② DMSO; ③ anhydrous ethanol; ④ the method for preparing free fatty acid solution of the present invention to prepare 8 mM free fatty acid storage solution, and observe the dissolution of the drug. The results are as follows: Figure 3 shown. Figure 3 After dissolving oleic acid and palmitic acid in PBS, a large amount of precipitation occurred, while the others were clear and transparent solutions. Then, 500 μM concentration (total concentration of oleic acid and palmitic acid) was added to the hepatic organoid culture medium to observe the precipitation of free fatty acid solution. The results are as follows: Figure 4 shown. Figure 4Among them, ② DMSO and ③ anhydrous ethanol both have different degrees of precipitation. Only the method for preparing free fatty acid solution of the present invention prepares 8 mM free fatty acid storage solution, which has no precipitation after being added to the liver organoid culture medium. It is a clear and transparent solution, which is conducive to the cultivation of non-alcoholic fatty liver organoid model with stable performance.

[0040] The method for preparing free fatty acid solution of the present invention is as follows: Take oleic acid and palmitic acid, prepare them into 200mM mother liquor with 100% ethanol respectively, and mix them in a volume ratio of 1:1 to prepare an exogenous free fatty acid (FFA) composition; take 10% BSA-PBS without FFA to couple the FFA in the exogenous free fatty acid composition with bovine serum albumin (BSA), let it stand in a 55℃ water bath for 15min until the solution is clear, and the final FFA storage concentration (total concentration of oleic acid and palmitic acid) is 8 mM, which is stored at -20℃.

[0041] Example 4 Free fatty acid loading induces steatosis A non-alcoholic fatty liver organoid model was obtained by adding 0 μM, 250 μM, 500 μM, and 750 μM (referring to the total concentration of oleic acid and palmitic acid in the liver organoid culture medium) free fatty acid solutions (the preparation method is shown in "the method for preparing free fatty acid solution of the present invention" in Example 3) to the liver organoid culture medium, incubating for 7 days to induce fatty degeneration of the organoids, and obtaining the liver organoid model.

[0042] Example 5 Nile red staining The non-alcoholic fatty liver organoid model prepared in Example 4 was collected. The collection steps were referred to the collection steps in Example 2. After fixation, 1 μM Nile Red fluorescent probe was added to the non-alcoholic fatty liver organoids and incubated at 37°C in the dark for 30 minutes. After washing with PBS three times, an anti-fluorescence quencher (including DAPI) was added, and a confocal fluorescence microscope was used to observe whether lipid droplets (Lipids) were formed (excitation wavelength: 552 nm, emission wavelength: 636 nm). The results are as follows Figure 5 As shown, 0 μM free fatty acids were used as the control group. On the 7th day after treatment with 0 μM, 250 μM, 500 μM, and 750 μM free fatty acid solutions, Nile red staining was used to detect the formation of lipid droplets in non-alcoholic fatty liver organoids to evaluate fatty degeneration.

[0043] The results showed that when the free fatty acid concentration reached 500 μM and 750 μM, the number of lipid droplets in liver organoids increased significantly, indicating that free fatty acids at concentrations of 500 μM and above can induce fatty degeneration of liver organoids.

[0044] Example 6 Liver function test The non-alcoholic fatty liver organoids prepared in Example 4 were cultured for three days, and the culture supernatant was taken to detect the concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG) and lactate dehydrogenase (LDH) using Mindray BS-200 fully automatic biochemical analyzer. The results are as follows Figure 6 As shown. The control group represents the non-alcoholic fatty liver organoids obtained after denaturation of 0 μM free fatty acids, and the FFA group represents the non-alcoholic fatty liver organoids obtained after denaturation of 500 μM free fatty acids. Compared with the control group, *p<0.05, **p<0.01. The results showed that 500 μM free fatty acids can significantly induce lipid accumulation and liver damage in liver organoids, and non-alcoholic fatty liver organoids were successfully constructed.

[0045] The above detailed description is a specific description of one feasible embodiment of the present invention. The embodiment is not intended to limit the patent scope of the present invention. Any equivalent implementation or modification that does not deviate from the present invention should be included in the scope of the technical solution of the present invention.

Claims

1. A method for preparing a non-alcoholic fatty liver organoid model, characterized in that: The method comprises contacting the liver organoid with a solution containing free fatty acids in a culture medium; wherein the concentration of the free fatty acids in the culture medium is at least 500 μM; The preparation method of the solution containing free fatty acids comprises the following steps: (1) Take oleic acid and palmitic acid and prepare solution A with 100% ethanol; (2) Mix the buffer solution containing bovine serum albumin with solution A until the solution becomes clear and transparent. Set aside.

2. The preparation method according to claim 1, characterized in that: The culture medium was made of Advanced DMEM / F12 medium supplemented with 10±1 mM 4-hydroxyethylpiperazineethanesulfonic acid, 1% glutamine, 1% penicillin-streptomycin, 2% B27, 1.25±0.1 mM N-acetylcysteine, 250±25ng / mL R-spondin-1, 50±5ng / mL EGF, 100±10ng / mL FGF10, 50±5ng / mL HGF, 10±1 nM gastrin, 10±1 mM nicotinamide, 3±0.3 μM CHIR99021, 1±0.1 μM A83-01 and 10±1 mM ROCK inhibitor Y-27632.

3. The preparation method according to claim 2, characterized in that: The culture medium was made of Advanced DMEM / F12 medium supplemented with 10 mM 4-hydroxyethylpiperazineethanesulfonic acid, 1% glutamine, 1% penicillin-streptomycin, 2% B27, 1.25 mM N-acetylcysteine, 250 ng / mL R-spondin-1, 50 ng / mL EGF, 100 ng / mL FGF10, 50 ng / mL HGF, 10 nM gastrin, 10 mM nicotinamide, 3 μM CHIR99021, 1 μM A83-01 and 10 mM ROCK inhibitor Y-27632.

4. The preparation method according to claim 1, characterized in that: In step (2), the buffer solution containing bovine serum albumin is mixed with solution A and then placed in a 55±5°C water bath for 15±5 minutes.

5. The preparation method according to claim 1, characterized in that: In step (1), 100% ethanol is first used to prepare oleic acid mother liquor and palmitic acid mother liquor, and then mixed to obtain solution A, wherein the concentration of the oleic acid mother liquor is 200±20 mM, and the concentration of the palmitic acid mother liquor is 200±20 mM.

6. The preparation method according to claim 1, characterized in that: The buffer solution containing bovine serum albumin in step (2) is a PBS solution containing 10±1% bovine serum albumin.

7. The preparation method according to claim 1, characterized in that: The free fatty acid is composed of oleic acid and palmitic acid, and the molar ratio of the free fatty acid and the palmitic acid is 1:1; the contact time is 5-7 days.

8. The preparation method according to claim 1, characterized in that: Prior to the contacting step, the liver organoids were dispersed in Matrigel.

9. A non-alcoholic fatty liver organoid model prepared according to the preparation method according to any one of claims 1-8.

10. Use of the non-alcoholic fatty liver organoid model according to claim 9 in drug screening.

Citation Information

Patent Citations

  • Method for establishing non-alcoholic fatty liver disease cell model

    CN109929794A

  • In-vitro fatty liver organ model, preparation method thereof and application of in-vitro fatty liver organ model in drug testing

    CN116426461A